Cardiovascular Disease
Conditions
Interventions
1+2:Aspirin=50mg/d+Aspiri>50mg/d
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Participants aged =60 years and be recommended to receive aspirin for cardiovascular prevention, volunteer to participate the study and sign the informed consent; 2. Participants can provide laboratory examination details (within 3 months) such as routine blood test, routine urine test, routine stool test, fecal occult-blood test, liver function, kidney function, electrolyte, blood glucose, serum lipid, uric acid and coagulation function, etc.
Exclusion criteria
Exclusion criteria: 1. Participants with allergies to aspirin, other salicylate drugs or any other ingredient of aspirin, a history of asthma caused by salicylate, substances contain salicylic acid or NSAIDs are not eligible after clinical assessment; 2. Participants have a life expectancy less than 3 years; 3. Participants who refuse to sign the informed consent, have a poor compliance of treatment or follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Composite outcome from the first major cardiovascular events including nonfatal myocardial infarction, unstable angina pectoris,arteriosclerotic disease requiring surgery or intervention,nonfatal stroke, transient ischemic attack and other cardiovascular causes (intracranial hemorrhage excluded); | — |
Secondary
| Measure | Time frame |
|---|---|
| Composite outcome from the first nonfatal Myocardial Infarction, nonfatal Stroke and Cardiovascular Death (intracranial hemorrhage excluded) Secondary indicator: Incidence of nonfatal Myocardial Infarction, Nonfatal Stroke or Cardiovascular Death (intracranial hemorrhage excluded) Secondary indicator: First unstable angina pectoris Secondary indi; | — |
Countries
China
Contacts
Public ContactLiu meilin
Peking University First Hospital
Outcome results
None listed